Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.
Melanoma
DRUG: MORAb028
Safety of multiple intralesional administration of MORAb-028, After each patient completes study treatment the patient is evaluated for dose limiting toxicities (DLTs) up to 1 week after their last dose (at day 33), Day 33
Maximum tolerated dose of intralesional administration of MORAb-028, 22 months
This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.